Prediction of human drug clearance by multiple metabolic pathways: Integration of hepatic and intestinal microsomal and cytosolic data

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 864-873

  Cubitt, Helen E ^a   Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; QUERCETIN; RALOXIFENE; SALBUTAMOL; TROGLITAZONE;

ACCURACY; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SULFATION; HUMAN; IN VITRO STUDY; INTESTINAL MICROSOME; INTESTINE; KIDNEY CLEARANCE; LIVER; LIVER MICROSOME; MICROSOME; PLASMA CLEARANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING;

CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; ENTEROCYTES; HUMANS; INTESTINES; METABOLIC CLEARANCE RATE; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN BINDING;

EID: 79955023850     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036566     Document Type: Article

References (48)

1. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45. (Pubitemid 46043890)
2. Boogaard PJ, Sumner SC, and Bond JA (1996) Glutathione conjugation of 1,2:3,4-diepoxybutane in human liver and rat and mouse liver and lung in vitro. Toxicol Appl Pharmacol 136:307-316. (Pubitemid 26070895)
3. Chen G, Zhang D, Jing N, Yin S, Falany CN, and Radominska-Pandya A (2003) Human gastrointestinal sulfotransferases: Identification and distribution. Toxicol Appl Pharmacol 187:186-197. (Pubitemid 36349350)
4. Coughtrie MW (2002) Sulfation through the looking glass-recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2:297-308. (Pubitemid 35439472)
5. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
6. Czock D, Keller F, Heringa M, and Rasche FM (2005) Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol 59:479-482. (Pubitemid 40523893)
7. Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, and Obach RS (2008) Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21:2260-2271.
8. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
9. Galetin A, Hinton LK, Burt H, Obach RS, and Houston JB (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693. (Pubitemid 47591312)
10. Galetin A and Houston JB (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318: 1220-1229. (Pubitemid 44268329)
11. Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y, Li W, Zhang Y, Tang Y, Zhang H, et al. (2010) Repaglinide-gemfibrozil drug interaction: Inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol 70:870-880.
12. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
13. Gertz M, Kilford PJ, Houston JB, and Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542. (Pubitemid 351397979)
14. Gibbs JP, Yang JS, and Slattery JT (1998) Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos 26:52-55. (Pubitemid 28071324)
15. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-726; author reply 727.
16. Hinton LK, Galetin A, and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplified by gemfibrozil- drug interactions. Pharm Res 25:1063-1074. (Pubitemid 351521103)
17. Hochner-Celnikier D (1999) Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23-29. (Pubitemid 29248779)
18. Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, Ikeda T, and Yamazoe Y (2002) Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949. (Pubitemid 34815426)
19. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22: 103-112. (Pubitemid 40558152)
20. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641. (Pubitemid 27167181)
21. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: Use of combined cytochrome P450 and UDPglucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
22. Lindsay J, Wang LL, Li Y, and Zhou SF (2008) Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 9:99-105. (Pubitemid 351460999)
23. Loi CM, Young M, Randinitis E, Vassos A, and Koup JR (1999) Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104. (Pubitemid 29431478)
24. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochem Pharmacol 71:1531-1539.
25. Mizuma T (2008) Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: Intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrate. J Pharm Sci 97:5471-5476.
26. Mizuma T (2009) Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140-141.
27. Mohutsky MA, Chien JY, Ring BJ, and Wrighton SA (2006) Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm Res 23:654-662.
28. Moon YJ, Wang L, DiCenzo R, and Morris ME (2008) Quercetin pharmacokinetics in humans. Biopharm Drug Dispos 29:205-217. (Pubitemid 351802843)
29. Mutch E, Nave R, McCracken N, Zech K, and Williams FM (2007) The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 73:1657-1664. (Pubitemid 46527549)
30. Nováková S, Van Dyck S, Glatz Z, Van Schepdael A, and Hoogmartens J (2004) Study of enzyme kinetics of phenol sulfotransferase by electrophoretically mediated microanalysis. J Chromatogr A 1032:319-326. (Pubitemid 38270376)
31. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
32. Pacifici GM, Giulianetti B, Quilici MC, Spisni R, Nervi M, Giuliani L, and Gomeni R (1997) (-)-Salbutamol sulphation in the human liver and duodenal mucosa: Interindividual variability. Xenobiotica 27:279-286. (Pubitemid 27140486)
33. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 283:1552-1562. (Pubitemid 28016533)
34. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, Knutson L, et al. (2003) Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 31:805-813. (Pubitemid 36617672)
35. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: An enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
36. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, and Lake BG (2002) Inhibition of zaleplon metabolism by cimetidine in the human liver: In vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 32:849-862. (Pubitemid 35155520)
37. Riches Z, Bloomer J, Patel A, Nolan A, and Coughtrie M (2009a) Assessment of cryopreserved human hepatocytes as a model system to investigate sulfation and glucuronidation and to evaluate inhibitors of drug conjugation. Xenobiotica 39:374-381.
38. Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009b) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: The SULT "pie." Drug Metab Dispos 37:2255-2261.
39. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
40. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: Implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
41. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2009) Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): Potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos 37:1395-1403.
42. Teubner W, Meinl W, Florian S, Kretzschmar M, and Glatt H (2007) Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404: 207-215. (Pubitemid 46849592)
43. Tukey RH and Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414. (Pubitemid 32179916)
44. Walle UK, Pesola GR, and Walle T (1993) Stereoselective sulphate conjugation of salbutamol in humans: Comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol 35:413-418. (Pubitemid 23103383)
45. Wynne HA, Wood P, Herd B, Wright P, Rawlins MD, and James OF (1992) The association of age with the activity of alcohol dehydrogenase in human liver. Age Ageing 21:417-420. (Pubitemid 23048662)
46. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
47. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, and Rodrigues AD (2007) Pharmacokinetic drug interactions involving 17β- ethinylestradiol: A new look at an old drug. Clin Pharmacokinet 46:133-157. (Pubitemid 46193058)
48. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.